Though P2X7 receptor inhibition has failed to control the short-term clinical symptoms of rheumatoid arthritis, preliminary results from preclinical and clinical testing indicate that it may prove to be powerful in reducing the unwanted skeletal effects of acute inflammatory states. This evidence concerns the gene P2RX7 and rheumatoid arthritis.